LetterReply
Dr. Balevic, et al, reply
Stephen J. Balevic, Christoph P. Hornik, Thomas P. Green, Megan E. Clowse, Daniel Gonzalez, Anil R. Maharaj, Laura E. Schanberg, Amanda M. Eudy, Geeta K. Swamy, Brenna L. Hughes and Michael Cohen-Wolkowiez
The Journal of Rheumatology May 2020, jrheum.200681; DOI: https://doi.org/10.3899/jrheum.200681
Stephen J. Balevic
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Christoph P. Hornik
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Thomas P. Green
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Megan E. Clowse
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Daniel Gonzalez
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Anil R. Maharaj
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Laura E. Schanberg
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Amanda M. Eudy
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Geeta K. Swamy
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Brenna L. Hughes
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Michael Cohen-Wolkowiez
Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA; Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Evanston, Illinois, USA; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; Duke Clinical Research Institute; Department of Rheumatology and Immunology, Duke University School of Medicine; Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine; PhD, Duke Clinical Research Institute. Salary and/or research support for this project was provided by the Rheumatology Research Foundation’s Scientist Development Award, the Thrasher Research Fund, the Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation, the Derfner Foundation, NIGMS/NICHD (2T32GM086330-06), NICHD (5R01-HD076676-04, HHSN275201000003I), and a Duke Health/Private Diagnostic Clinic ENABLE grant. Dr. Schanberg serves on the data and safety monitoring board for Sanofi (sarilumab). Sanofi is a maker of hydroxychloroquine. Dr. Swamy chairs the Independent Data Monitoring Committee for GlaxoSmithKline (RSV vaccine trials). Dr. Cohen-Wolkowiez receives support for research from industry for drug development in adults and children. Address correspondence to Dr. S.J. Balevic, Department of Rheumatology and Immunology, Duke University School of Medicine, 2301 Erwin Road, CHC, T-Level, Durham,
Abstract
We read with great interest the very thoughtful commentary by Joob and Wiwanitkit1. We agree with the authors that, despite conflicting clinical data to date, it is possible that hydroxychloroquine (HCQ) may have a protective effect in the setting of the coronavirus disease 2019 (COVID‑19).
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Dr. Balevic, et al, reply
Stephen J. Balevic, Christoph P. Hornik, Thomas P. Green, Megan E. Clowse, Daniel Gonzalez, Anil R. Maharaj, Laura E. Schanberg, Amanda M. Eudy, Geeta K. Swamy, Brenna L. Hughes, Michael Cohen-Wolkowiez
The Journal of Rheumatology May 2020, jrheum.200681; DOI: 10.3899/jrheum.200681
Dr. Balevic, et al, reply
Stephen J. Balevic, Christoph P. Hornik, Thomas P. Green, Megan E. Clowse, Daniel Gonzalez, Anil R. Maharaj, Laura E. Schanberg, Amanda M. Eudy, Geeta K. Swamy, Brenna L. Hughes, Michael Cohen-Wolkowiez
The Journal of Rheumatology May 2020, jrheum.200681; DOI: 10.3899/jrheum.200681